Implanet Stands out at the North American Spine Society (NASS) Annual Meeting and Signs Six New Distribution Agreements

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, reports that its JAZZ implant was the object of significant interest from specialized spine professionals and distributors at the recent North American Spine Society (NASS) Annual Meeting in San Francisco.

This year’s NASS congress, the largest professional event for spine professionals, brought together over 2,800 surgeons. This congress provides an opportunity for spine professionals to meet every year in order to share the latest information, techniques, innovative procedures and best practices in the field of spine surgery. Implanet’s exhibit, featuring the JAZZ technology platform, produced considerable interest amongst numerous renowned spine surgeons affiliated with top institutions, both in the United States and Abroad.

During this event, Implanet signed 6 additional distribution agreements, increasing its total number of sales agencies in the United States to 20, thus continuing the ongoing acceleration of its commercial deployment.

"The outcome of this congress was very positive for us, with substantial interest in our JAZZ implant and its development. Surgeons and distributors showed a high level of interest in its technical properties, its ease of insertion and associated instrumentation, all of which provide substantial clinical benefit. More than 20 follow up appointments have been scheduled for the coming weeks. The success of our participation in this major event will play a substantial role in the world wide adoption of JAZZ”, says Ludovic Lastennet, CEO of Implanet.

Moreover, this month the Company also took part in the SOFCOT (Société Française de Chirurgie Orthopédique et Traumatologique) congress. SOFCOT brings together, every year in Paris, French orthopedic surgeons and professionals. During this congress, Implanet presented to an audience of selected surgeons its planned additions to the Madison knee prosthesis range.

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2013 sales of €6.7 million. For further information, please visit www.implanet.com.

IMPLANET is listed on Compartment C of Euronext™ Paris.
Ticker: IMPL - ISIN code: FR0010458729